Pfizer
on Tuesday laid out guidance for the 2023 fiscal year well below Wall Street consensus figures, tempering investor expectations ahead of what it expects to be a steep drop in Covid-19 product sales.
Shares fell 3% in premarket trading on the downbeat guidance.
